Berobenatide

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

1

Maridebart Cafraglutide

Amgen

Phase 3

72

Retatrutide

Eli Lilly

Phase 3

63

NNC0487-0111

Novo Nordisk

Phase 3

114

Gemtesa

Sumitomo Pharma America, Inc.

Phase 3

15

Zenagamtide

Novo Nordisk

Phase 3

36

Ribupatide

KKailera

Phase 3

37

Elecoglipron

AstraZeneca

Phase 3

18

PF-08653944

Pfizer

Phase 3

59

Berobenatide

Pfizer

Phase 3

310

Survodutide

Boehringer Ingelheim

Phase 3

2Show 36 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Obesity3 trials

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH OBESITY DISEASE IN JAPAN (VESPER-JM)

Not yet recruiting·Pfizer·Phase 3·NCT07794774·197 enrolled

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-WEEKLY BEROBENATIDE IN ADULTS WITH OBESITY DISEASE IN JAPAN (VESPER-JW)

Not yet recruiting·Pfizer·Phase 3·NCT07794761·180 enrolled

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-WEEKLY PF-08653944 IN CHINESE ADULTS WITH OVERWEIGHT OR OBESITY

Not yet recruiting·Pfizer·Phase 3·NCT07792954·300 enrolled

Apnea1 trial

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH OBSTRUCTIVE SLEEP APNEA AND OVERWEIGHT OR OBESITY RECEIVING POSITIVE AIRWAY PRESSURE THERAPY (VESPER-OSA 1)

Not yet recruiting·Pfizer·Phase 3·NCT07823608·258 enrolled

Details

Drug Info

Related News